| 1. | EXECUTIVE SUMMARY | 
| 1.1. | Scope of the report | 
| 1.2. | Benefits of electronic skin patches as a form factor | 
| 1.3. | Market push and pull drivers | 
| 1.4. | Skin patch applications overview | 
| 1.5. | Diabetes management devices: electronic skin patches increase patient comfort | 
| 1.6. | Diabetes management device roadmap:  Glucose sensors | 
| 1.7. | Key points for diabetes management devices: continuous glucose monitoring | 
| 1.8. | Diabetes management device roadmap:  Insulin delivery | 
| 1.9. | Key points for diabetes management devices: insulin delivery | 
| 1.10. | Atrial fibrillation: electronic skin patches addresses key industry pain points | 
| 1.11. | Diagnosis process for atrial fibrillation and other arrhythmias | 
| 1.12. | Key points for cardiac monitoring: Holter, mobile cardiac telemetry & event monitor | 
| 1.13. | Vital sign monitoring: electronic skin patches increase patient mobility | 
| 1.14. | Emerging application: Decentralized clinical trials | 
| 1.15. | Key points for general vital sign monitoring | 
| 1.16. | Other applications: temperature, electrical stimulation, iontophoresis and sweat sensing | 
| 1.17. | Electronic skin patch manufacturing process | 
| 1.18. | Material requirements for an electronic skin patch | 
| 1.19. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 | 
| 1.20. | Electronic skin patches global market annual revenue forecast 2022-2033 | 
| 2. | INTRODUCTION | 
| 2.1. | How to use this report | 
| 2.2. | Definitions | 
| 2.3. | The case for skin patches: augmenting the human body | 
| 2.4. | Electronic skin patches within wearable technology progress | 
| 2.5. | Benefits of electronic skin patches as a form factor | 
| 2.6. | Market push and pull drivers | 
| 2.7. | Key milestones in the history of skin patches | 
| 2.8. | COVID-19 effect on electronic skin patches | 
| 2.9. | Privacy and IT challenges | 
| 2.10. | Reimbursement drives commercial business models | 
| 2.11. | Reimbursement codes (US) | 
| 2.12. | Skin patch applications overview | 
| 2.13. | Skin patch applications overview | 
| 2.14. | Skin patch applications overview | 
| 3. | DIABETES MANAGEMENT VIA SKIN PATCHES | 
| 3.1.1. | Background: Introduction to diabetes | 
| 3.1.2. | The prevalence of diabetes | 
| 3.1.3. | Diabetes management ecosystem | 
| 3.1.4. | Background: Diabetes on the rise | 
| 3.1.5. | Diabetes management device roadmap: Summary | 
| 3.1.6. | Electronic skin patches in diabetes management: company profiles | 
| 3.2. | Continuous glucose monitoring | 
| 3.2.1. | Diabetes management device roadmap: Glucose sensors | 
| 3.2.2. | Continuous glucose monitors (CGMs) take the form of skin patches | 
| 3.2.3. | CGMs are superseding test strips | 
| 3.2.4. | CGM reimbursement for type 2 is currently limited | 
| 3.2.5. | CGM usage in hospitals | 
| 3.2.6. | Anatomy of a typical CGM device | 
| 3.2.7. | CGM: Technology | 
| 3.2.8. | CGM sensor manufacturing and anatomy | 
| 3.2.9. | Comparison metrics for CGM devices | 
| 3.2.10. | Example: Accuracy of CGM devices over time | 
| 3.2.11. | CGM: Overview of key players | 
| 3.2.12. | Abbott Laboratories: CGM business | 
| 3.2.13. | Dexcom: Introduction | 
| 3.2.14. | Medtronic: Introduction | 
| 3.2.15. | Ascensia, POCTech and Yuwell | 
| 3.2.16. | Senseonics | 
| 3.2.17. | Non-invasive glucose monitoring | 
| 3.2.18. | Conclusions for continuous glucose monitors | 
| 3.2.19. | Insulin pumps | 
| 3.2.20. | Insulin delivery: Introduction | 
| 3.2.21. | Diabetes management device roadmap:  Insulin delivery | 
| 3.3. | Insulin Pumps | 
| 3.3.1. | Insulin patch pumps | 
| 3.3.2. | Insulin pump market | 
| 3.3.3. | Insulin pump players and market share | 
| 3.3.4. | Key trends for the industry | 
| 3.3.5. | Accu-Chek Solo by Roche | 
| 3.3.6. | What do patch pumps offer over infusion pumps? | 
| 3.3.7. | Insulin pump technology roadmap | 
| 3.4. | Linking insulin pumps and CGM: Towards closed loop and the artificial pancreas | 
| 3.4.1. | Today: Hybrid closed loop systems | 
| 3.4.2. | The objective: Closing the feedback loop | 
| 3.4.3. | Medtronic leads development of hybrid closed-loop | 
| 3.4.4. | Insulet: Omnipod 5 | 
| 3.4.5. | Tidepool: Tidepool Loop | 
| 3.4.6. | Outlook for insulin pumps | 
| 3.4.7. | Conclusions for insulin delivery | 
| 4. | CARDIAC RHYTHM MONITORING SKIN PATCHES | 
| 4.1.1. | Cardiovascular disease (CVD) | 
| 4.1.2. | Atrial fibrillation and early detection | 
| 4.1.3. | Biopotential indicator and the electrocardiogram | 
| 4.1.4. | Diagnosis process for atrial fibrillation and other arrhythmias | 
| 4.1.5. | ECG monitor pain points that skin patches solve | 
| 4.1.6. | Cardiac monitoring skin patches: device types | 
| 4.1.7. | Cardiac monitoring device types - skin patches | 
| 4.1.8. | Cardiac rhythm monitoring skin patches: companies and product types | 
| 4.1.9. | Cardiac monitoring players and devices (1) | 
| 4.1.10. | Cardiac monitoring players and devices (2) | 
| 4.1.11. | How many ECG channels does a skin patch need? | 
| 4.1.12. | ECGs use wet electrodes and strong adhesives | 
| 4.1.13. | Dry electrodes may improve longer wear experience | 
| 4.1.14. | ECG skin patches are packaged with support AI | 
| 4.1.15. | Reimbursement codes for wearable cardiac monitors | 
| 4.1.16. | Wearable vs implantable monitoring | 
| 4.1.17. | Phillips (Biotelemetry) | 
| 4.1.18. | iRhythm | 
| 4.1.19. | Boston Scientific (Preventice Solutions) | 
| 4.1.20. | Conclusions for cardiac monitoring skin patches | 
| 4.1.21. | Cardiac rhythm monitoring skin patches: company profiles | 
| 4.2. | Fetal heart rate monitoring | 
| 4.2.1. | Fetal monitoring | 
| 4.2.2. | GE Healthcare (Monica Healthcare) | 
| 4.2.3. | Conclusions for fetal heart rate monitoring | 
| 5. | GENERAL PATIENT MONITORING SKIN PATCHES | 
| 5.1. | General vital sign monitoring | 
| 5.2. | Drivers and requirements for skin patches | 
| 5.3. | Application potential for general purpose devices | 
| 5.4. | Deployment challenges for general monitoring devices | 
| 5.5. | Evolving market dynamics over time | 
| 5.6. | Decentralized clinical trials | 
| 5.7. | General patient monitoring skin patch players | 
| 5.8. | Inpatient monitoring | 
| 5.9. | Going wireless | 
| 5.10. | Shifting to outpatient monitoring | 
| 5.11. | Post-Discharge Monitoring: Reducing Readmissions | 
| 5.12. | Neutropenia, post-chemotherapy vital monitoring | 
| 5.13. | Drawback of remote patient monitoring | 
| 5.14. | BioIntelliSense | 
| 5.15. | Vivalink | 
| 5.16. | VitalConnect | 
| 5.17. | Conclusions for general patient monitoring skin patches | 
| 6. | TEMPERATURE SENSING SKIN PATCHES | 
| 6.1. | Body temperature | 
| 6.2. | Skin patches for temperature sensing | 
| 6.3. | Temperature sensor options | 
| 6.4. | Fever and COVID-19 | 
| 6.5. | Fertility monitoring | 
| 6.6. | Temperature monitor skin patch companies | 
| 6.7. | Blue Spark | 
| 6.8. | Conclusions for temperature monitoring skin patches | 
| 7. | ELECTRICAL STIMULATION WITH SKIN PATCHES | 
| 7.1. | Introduction | 
| 7.2. | Differentiation of electrical stimulation | 
| 7.3. | NMES, EMS, and FES | 
| 7.4. | Application of NMES/EMS | 
| 7.5. | Electrical stimulation parameters | 
| 7.6. | First Kind Medical: gecko | 
| 7.7. | TENS | 
| 7.8. | Percutaneous Electrical Stimulation | 
| 7.9. | Communication with Bioelectronic Implants | 
| 7.10. | Electrical stimulation skin patches: company profiles | 
| 7.11. | Conclusions for electrical stimulation skin patches | 
| 8. | IONTOPHORESIS SKIN PATCHES | 
| 8.1. | Introduction | 
| 8.2. | Iontophoresis for Drug Delivery | 
| 8.3. | Commercial Activity: Iontophoresis for Drug Delivery | 
| 8.4. | Iontophoresis for Drug Delivery: Companies | 
| 8.5. | Reverse Iontophoresis | 
| 8.6. | Nemaura Medical | 
| 8.7. | Conclusions for iontophoresis and reverse iontophoresis skin patches | 
| 9. | SWEAT SENSING SKIN PATCHES | 
| 9.1. | Introduction | 
| 9.2. | Galvanic Skin Response | 
| 9.3. | Chemical Sensing in Sweat | 
| 9.4. | Analytes in Sweat | 
| 9.5. | Sweat Sensing: Companies | 
| 9.6. | Conclusion for sweat sensing | 
| 10. | OTHER ELECTRONIC SKIN PATCH APPLICATIONS | 
| 10.1. | Wound Monitoring | 
| 10.2. | Wound Monitoring: Examples | 
| 10.3. | Wound Treatment: Potential Directions | 
| 10.4. | Motion | 
| 10.5. | Motion: Skin Patches vs Other Form Factors | 
| 10.6. | Motion: Inertial Measurement Units and Concussion Monitoring | 
| 10.7. | Motion: Displacement Sensors | 
| 10.8. | Communication with Implants | 
| 10.9. | Communication with Implants: Proteus Digital Health | 
| 10.10. | Ultrasound: Bladder Volume Sensing | 
| 10.11. | Respiration Sound | 
| 11. | MANUFACTURING ELECTRONIC SKIN PATCHES | 
| 11.1.1. | Electronic skin patch manufacturing value chain | 
| 11.2. | Manufacturing methods | 
| 11.2.1. | Electronic skin patch manufacturing process | 
| 11.2.2. | Higher volumes will encourage transition to R2R manufacturing | 
| 11.2.3. | Offering S2S and R2R production enables different order sizes | 
| 11.2.4. | Increased demand for wearable/medical manufacturing leads to expansion plans | 
| 11.2.5. | Membrane switch manufacturers with screen printing capabilities transition to electronic skin patches | 
| 11.2.6. | Interest in wearable sensing continues to grow but technical challenges remain | 
| 11.2.7. | Development from conventional boxed to flexible hybrid electronics will be challenging | 
| 11.2.8. | GE Research: Manufacturing of disposable wearable vital signs monitoring devices | 
| 11.2.9. | NextFlex: Utilizing electronics in silicone to make more comfortable skin patches | 
| 11.2.10. | Key points: Electronic skin patch manufacturing | 
| 11.3. | Materials | 
| 11.3.1. | 'Full-stack' material portfolios reduce adoption barriers | 
| 11.3.2. | Material requirements for an electronic skin patch | 
| 11.3.3. | Progress in using liquid metal alloys as stretchable inks for wearable electronics | 
| 11.3.4. | New printed electrode materials from Henkel | 
| 11.3.5. | Key points: Materials for electronic skin patches | 
| 12. | MARKET FORECASTS | 
| 12.1.1. | Electronic skin patches global market annual revenue historic data 2010-2022 | 
| 12.1.2. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 | 
| 12.1.3. | Electronic skin patches global market annual revenue historic data and forecast 2010-2033 - excluding diabetes | 
| 12.2. | Diabetes management skin patch market forecasts | 
| 12.2.1. | Forecast: introduction | 
| 12.2.2. | Forecast method: Company revenue in diabetes management | 
| 12.2.3. | Skin patches for diabetes management: market forecast 2022-2033 | 
| 12.2.4. | CGM: annual revenue forecast 2022-2033 | 
| 12.2.5. | CGM: methodology and assumptions | 
| 12.2.6. | CGM: forecasted uptake by type 2 and prediabetes | 
| 12.2.7. | CGM: Milestones | 
| 12.2.8. | CGMs by population adoption proportion | 
| 12.2.9. | Patch pumps revenue forecast 2023-2033 | 
| 12.3. | Cardiac rhythm monitoring skin patch market forecasts | 
| 12.3.1. | Cardiac rhythm management forecasting methodology | 
| 12.3.2. | Cardiac rhythm management global historic market data 2010-2021 | 
| 12.3.3. | Cardiac rhythm management global market forecast 2021-2033 | 
| 12.3.4. | Cardiac rhythm management global market forecast 2010-2033 | 
| 12.3.5. | Cardiac rhythm management global market forecast 2010-2033 | 
| 12.4. | General patient monitoring skin patch market forecasts | 
| 12.4.1. | Methodology for forecasting general patient monitoring | 
| 12.4.2. | General patient monitoring skin patches global market forecast 2023-2033 | 
| 12.4.3. | General patient monitoring skin patches global market historic data and forecast 2010-2033 | 
| 12.5. | Temperature sensing skin patch market forecasts | 
| 12.5.1. | Temperature sensing skin patches global market forecast 2023-2033 | 
| 12.6. | Electrical stimulation skin patch market forecasts | 
| 12.6.1. | Electrical stimulation skin patches: market data (2010-2020) | 
| 12.6.2. | Electrical stimulation skin patches: market forecast (2021-2033) | 
| 12.6.3. | Electrical stimulation skin patches: market data and forecast (2010-2033) | 
| 12.7. | Iontophoresis skin patch market forecasts | 
| 12.7.1. | Iontophoresis skin patches: market forecast (2021-2033) | 
| 12.7.2. | Iontophoresis skin patches: market data and forecast (2010-2033) | 
| 13. | COMPANY PROFILES | 
| 13.1. | Abbott Diabetes care | 
| 13.2. | Agamatrix | 
| 13.3. | Biobeat | 
| 13.4. | BiointelliSense | 
| 13.5. | Bioness | 
| 13.6. | Bittium | 
| 13.7. | Blue Spark | 
| 13.8. | Boston Scientific (Preventice solutions) | 
| 13.9. | Byteflies | 
| 13.10. | Cardiomo | 
| 13.11. | Cortrium | 
| 13.12. | Dexcom | 
| 13.13. | Diabeloop | 
| 13.14. | Epicore | 
| 13.15. | FirstKind | 
| 13.16. | GlucoRx | 
| 13.17. | Grapheal | 
| 13.18. | HiDow | 
| 13.19. | Hivox Biotek | 
| 13.20. | Infinovo | 
| 13.21. | iRhythm | 
| 13.22. | Isansys | 
| 13.23. | Leaf Healthcare | 
| 13.24. | LifeScience Technology | 
| 13.25. | LifeSignals | 
| 13.26. | Medtronic | 
| 13.27. | Medtrum | 
| 13.28. | Mezoo | 
| 13.29. | Philips | 
| 13.30. | Phillips Biotelemetry | 
| 13.31. | Preventice Solutions | 
| 13.32. | QT Medical | 
| 13.33. | Raiing | 
| 13.34. | Roche | 
| 13.35. | Rooti | 
| 13.36. | Scottcare | 
| 13.37. | Seers technology | 
| 13.38. | Sigknow | 
| 13.39. | Singular Wings Medical | 
| 13.40. | SPR Therapeutics | 
| 13.41. | SteadySense | 
| 13.42. | The surgical company | 
| 13.43. | Tidepool | 
| 13.44. | Triple W | 
| 13.45. | VitalConnect | 
| 13.46. | Vivalink |